Sign In
Buy RHHBY
$49.06
-0.130 (-0.264%)
At Close: Jun 03, 2026
Roche to Acquire CAR-T Cell Therapy Focused Poseida for $1.5B
12:00pm, Tuesday, 26'th Nov 2024
RHHBY is all set to acquire Poseida Therapeutics, Inc. and ramp up its pipeline with off-the-shelf cell therapies.
Unity Bank's Amanda Roche Honored as a New Leader in Banking by NJ Bankers Association
11:28am, Tuesday, 26'th Nov 2024
Prestigious Recognition Celebrates Rising Stars in New Jersey's Banking Industry Prestigious Recognition Celebrates Rising Stars in New Jersey's Banking Industry
On Tuesday, Roche Holdings AG RHHBY agreed to acquire Poseida Therapeutics, Inc. PSTX for an equity value of approximately $1.5 billion on a fully diluted basis.
Roche records setback in phase III study of two lung cancer drugs
01:46am, Tuesday, 26'th Nov 2024
A Roche study into using a combination of tiragolumab and tecentriq to treat a form of lung cancer in a phase III trial did not achieve the desired success, the Swiss pharmaceuticals maker said on Tue
Roche to acquire US-based Poseida Therapeutics
01:29am, Tuesday, 26'th Nov 2024
Roche will acquire California-based biopharmafirm Poseida Therapeutics for $9 per share at closing, for a total equity value of $1 billion, the Swiss company said on Tuesday.
Basel, 26 November 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has entered into a definitive merger agreement to acquire Poseida Therapeutics, Inc. (“Poseida”, NASDAQ: PSTX),
Poseida Therapeutics, Inc. Announces Agreement to be Acquired by Roche Holdings, Inc.
01:10am, Tuesday, 26'th Nov 2024
Poseida stockholders to receive up to $13.00 per share in cash, comprised of $9.00 per share in cash at closing and a non-tradeable contingent value right (CVR) to receive up to an aggregate of $4.00
Genentech Reports Update on Phase III SKYSCRAPER-01 Study Results
01:00am, Tuesday, 26'th Nov 2024
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), reports an update on the Phase III SKYSCRAPER-01 study, evaluating tiragolumab combin
Roche reports update on Phase III SKYSCRAPER-01 study results
01:00am, Tuesday, 26'th Nov 2024
Basel, 26 November 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) reports an update on the phase III SKYSCRAPER-01 study, evaluating tiragolumab combined with Tecentriq® (atezolizumab) compared to Tecentr
The PATHWAY HER2 (4B5) test helps to identify patients with previously-treated, unresectable or metastatic HER2-positive biliary tract cancer (BTC) who may be eligible for treatment with ZIIHERA. The
Franklin International Equity Fund Q3 2024 Commentary
04:45am, Friday, 22'nd Nov 2024
Jinda Noipho Performance Data Average Annual Total Returns 4(%) 1 Mth 3 Mths 1 Year 3 Year 5 Year 10 Year Since Inception Inception Date Class C (MUTF:LMGEX) - With Sales Charges a -1.46 4.15 21.61 5.
Neuron23 Announces Usage of Roche's Digital Biomarker and Device in Parkinson's Disease Clinical Trial
07:30am, Tuesday, 19'th Nov 2024
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #LRRK2--Neuron23 is using a Roche-developed digital biomarker as the primary endpoint in the Phase 2 NEULARK trial of NEU-411 in early Parkinson's diseas
The VENTANA FOLR1 (FOLR1-2.1) RxDx Assay detects the folate receptor 1 protein (FOLR1 or FRɑ), which is over-expressed in most ovarian cancers. The test identifies ovarian cancer patients eligible fo
Flare Therapeutics Inc., a GordonMD® Global Investments LP Portfolio Company, Enters Strategic Discovery Collaboration with Roche
09:20am, Thursday, 14'th Nov 2024
BEVERLY HILLS, Calif.--(BUSINESS WIRE)--GordonMD® Global Investments LP announced today that its portfolio company, Flare Therapeutics Inc., has entered into a strategic discovery collaboration with
Collaboration will leverage Flare Therapeutics' proteomic and mass spectrometry platform and expertise, powered by its proprietary library of electrophilic compounds, to discover novel small molecule
